ClinicalTrials.gg
CompletedNCT03661528Updated Jul 3, 2024Results posted

Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor

A Phase 4 interventional study of andexanet alfa and Usual Care in Acute Intracranial Hemorrhage, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 142 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
530
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Thrombosis with a site in Germany — 3 open to participants now, 4 under way, none of them phase 3. Thrombosis · Germany.

Enrollment
11th of 33
530 · median 229
Started
2019
with 3 others
Phase 4
5 of 54
none open now
Registered
41st of 54
by date
Lead sponsor
2 of 54
Alexion Pharmaceuticals, Inc.

Among the 54 studies in Thrombosis with a site in Germany, this one is the 11th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2019, is one of 5 in phase 4, and was the 41st registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

3 of the 54 studies in Thrombosis with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Thrombosis with a site in Germany, or all of them as a file.
02

Study summary

Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet alfa versus usual care in patients with intracranial hemorrhage anticoagulated with a direct oral FXa anticoagulant

Read the detailed description

This is a randomized, multicenter clinical trial designed to determine the efficacy and safety of andexanet alfa compared to usual care in patients presenting with acute intracranial hemorrhage within 6 hours of symptom onset to baseline scan and within 15 hours of taking an oral factor Xa inhibitor. The study will use a prospective, randomized, open label (PROBE) design. The primary efficacy outcome will be adjudicated by a blinded Endpoint Adjudication Committee. To support the adjudication of hemostatic efficacy, a blinded Imaging Core Laboratory will review all available scans. Between 900 and 1200 patients are planned to be enrolled in the study.

03

Conditions studied

  • Acute Intracranial Hemorrhage

Browse trials for

Keywords

  • thrombosis
  • anticoagulant
  • acute intracranial hemorrhage
  • andexanet alfa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written . Either the patient or his or her medical proxy (or legally authorized representative if permissible by local or regional laws and regulations) has been adequately informed of the nature and risks of the study and has given written informed consent prior to Screening.

    • Deferred consent procedure is allowed where approved by local ethics committees. In cases of deferred consent, the time of the study physician's documented decision to include the patient into the study will serve as "time of consent" with respect to protocol-specific procedures.
    • In all cases where the patient does not sign informed consent prior to study entry, informed consent from the patient will be obtained as soon as realistically possible after inclusion in the trial and in accordance with the Declaration of Helsinki, International Conference on Harmonization-Good Clinical Practice (GCP), the EU General Data Protection Regulation (GDPR) and national and local regulations.
  2. Age ≥ 18 years old at the time of consent.
  3. An acute intracerebral bleeding episode, defined as an estimated blood volume ≥ 0.5 to ≤ 60 mL acutely observed radiographically within the cerebrum. Patients may have extracerebral (e.g., subdural, subarachnoid, epidural) or extracranial (e.g., gastrointestinal, intraspinal) bleeding additionally, but the intracerebral hemorrhage must be considered the most bleed at the time of enrollment.
  4. Performance of a head CT or MRI scan demonstrating the intracerebral bleeding within 2 hours prior to randomization (the baseline scan may be repeated only once to meet this criterion).
  5. Treatment with an oral FXa inhibitor (apixaban [last dose 2.5 mg or greater], rivaroxaban [last dose 10 mg or greater], or edoxaban [last dose 30 mg or greater]):

    • ≤ 15 hours prior to randomization.
    • > 15 hours prior to randomization or unknown time of last dose, if documented anti fXa activity is > 100 ng/mL for direct fXa inhibitors (apixaban, rivaroxaban or edoxaban) may be enrolled, irrespective of the time of the last dose, and the local anti-fXa activity level is obtained within 2 hours prior to consent, performed as per standard of care. Note: Patients enrolled in this manner should receive a high andexanet dosing regimen.
  6. Time from bleeding symptom onset \< 6 hours prior to the baseline imaging scan. Time of trauma (if applicable) or time last seen normal may be used as surrogates for time of symptom onset. (If the baseline scan is repeated to meet Inclusion Criterion #4, the time from bleeding symptom onset must be \< 6 hours prior to the repeat baseline imaging scan.)
  7. Female patients of and male patients with female partners of childbearing potential must follow protocol-specified guidance for avoiding pregnancy for 30 days after the last dose of study drug.
  8. Have a negative pregnancy test documented prior to enrollment (for females of childbearing potential).
  9. NIHSS score ≤ 35 at the time of consent.

Exclusion criteria

Exclusion Criteria

If a patient meets any of the following criteria, he or she is not eligible to participate in this trial:

  1. Planned surgery, including Burr holes for hematoma drainage, within 12 hours after randomization. Minimally invasive surgery/procedures not directly related to the treatment of intracranial bleeding and that are not expected to significantly affect hematoma volume are allowed (e.g., Burr holes for intracranial pressure monitoring, endoscopy, bronchoscopy, central lines.
  2. GCS score \< 7 at the time of consent. If a patient is intubated and/or sedated at the time of consent, they may be enrolled if it can be documented that they were intubated/sedated for non-neurologic reasons within 2 hours prior to consent.
  3. Purposefully left blank.
  4. Anticipation that the baseline and follow up brain scans will not be able to use the same imaging modalities (i.e., patients with a baseline CT scan should have a CT scan in follow up; similarly, for MRI).
  5. Expected survival of less than 1 month (not related to the intracranial bleed).
  6. Recent history (within 2 weeks) of a diagnosed TE or symptoms of the following:

    ○ Venous Thromboembolism (VTE: e.g., deep venous thrombosis, PE, cerebral venous thrombosis), myocardial infarction (MI), Disseminated Intravascular Coagulation (DIC), cerebral vascular accident, (TIA), acute coronary syndrome, or arterial systemic embolism.

  7. Acute decompensated heart failure or cardiogenic shock at the time of randomization.
  8. Severe sepsis or septic shock at the time of randomization.
  9. The patient is a pregnant or lactating female.
  10. Receipt of any of the following drugs or blood products within 7 days prior to consent:

    1. VKA (e.g., warfarin).
    2. Dabigatran.
    3. PCC (e.g., KCentra®) or rfVIIa (e.g., NovoSeven®), or anti-inhibitor coagulant complex (e.g., FEIBA®), FFP, and whole blood.
  11. Past use of andexanet (or planned use of commercial andexanet).
  12. Treatment with an drug \< 30 days prior to consent.
  13. Any tumor-related bleeding.
  14. Known to any component of andexanet.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
530 participants (actual)

Study arms

  • Experimental
    andexanet alfa

    Patients will receive one of two dosing regimens of andexanet alfa based on which FXa inhibitor they received and the amount and timing of the most recent dose.

    Drug: andexanet alfa

  • Other
    Usual Care

    Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.

    Drug: Usual Care

Interventions

  • Andexanet alfa is a recombinant version of human FXa

  • DrugUsual Care

    Usual care will consist of any treatment(s) (including no treatment) other than andexanet alfa administered within 3 hours post-randomization that the Investigator and/or other treating physicians consider to be appropriate.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved Effective Hemostasis

    Effective hemostasis was defined as a change from baseline in National Institutes of Health Stroke Scale (NIHSS) of + 6 or less at the 12 hour timepoint and ≤35% increase in haematoma volume compared to baseline on a repeat computed tomography (CT) or magnetic resonance imaging (MRI) scan at 12 hours and no rescue therapies administered between 3 hours and 12 hours after randomization (defined as excellent or good hemostasis). The NIHSS is a validated quantitative assessment tool to measure stroke-related neurological deficits and ranges from 0 (no neurological deficits) to a maximum of 42, indicative of a very severe level of impairment. Data presented is for the number of participants who achieved effective hemostasis (excellent or good hemostasis), as adjudicated by the independent Endpoint Adjudication Committee (IEAC).

    Time frame: Baseline up to 12 hours

Secondary outcomes

  1. Percentage Change From Baseline to Nadir in Anti-FXa Activity

    Anti-FXa activity was measured from plasma samples to assess the anticoagulant status of FXa inhibitors using a modified chromogenic assay performed at a Central Laboratory. Nadir was defined as the minimum anti-FXa activity post-randomization.

    Time frame: Baseline up to 2 hours

07

Results

Posted Jul 3, 2024

Participant flow

Participant flow — Overall Study
MilestoneAndexanet AlfaUsual Care
Started263267
Received at least 1 dose of study drug262265
Completed180193
Not completed8374
Withdrew: Death10
Withdrew: Physician decision31
Withdrew: Other than specified52
Withdrew: Withdrawal by subject53
Withdrew: Disease progression813
Withdrew: Adverse event6155

Outcome measures

PrimaryNumber of Participants Who Achieved Effective Hemostasis

Effective hemostasis was defined as a change from baseline in National Institutes of Health Stroke Scale (NIHSS) of + 6 or less at the 12 hour timepoint and ≤35% increase in haematoma volume compared to baseline on a repeat computed tomography (CT) or magnetic resonance imaging (MRI) scan at 12 hours and no rescue therapies administered between 3 hours and 12 hours after randomization (defined as excellent or good hemostasis). The NIHSS is a validated quantitative assessment tool to measure stroke-related neurological deficits and ranges from 0 (no neurological deficits) to a maximum of 42, indicative of a very severe level of impairment. Data presented is for the number of participants who achieved effective hemostasis (excellent or good hemostasis), as adjudicated by the independent Endpoint Adjudication Committee (IEAC).

Time frame:
Baseline up to 12 hours
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Effective Hemostasis
ParticipantsAndexanet AlfaUsual Care
Number of Participants Who Achieved Effective Hemostasis150121
Statistical analysis
  • Andexanet Alfa vs Usual Care · Cochran-Mantel-Haenszel · p = 0.0032 · Percentage proportion difference: 13.4 · 95% CI 4.6 to 22.2
SecondaryPercentage Change From Baseline to Nadir in Anti-FXa Activity

Anti-FXa activity was measured from plasma samples to assess the anticoagulant status of FXa inhibitors using a modified chromogenic assay performed at a Central Laboratory. Nadir was defined as the minimum anti-FXa activity post-randomization.

Time frame:
Baseline up to 2 hours
Reported as:
Median · Percent change
Percentage Change From Baseline to Nadir in Anti-FXa Activity
Percent changeAndexanet AlfaUsual Care
Percentage Change From Baseline to Nadir in Anti-FXa Activity-94.41 (-99.1 to 1805.0)-27.46 (-97.9 to 416.0)
Statistical analysis
  • Andexanet Alfa vs Usual Care · ANCOVA · p = <0.0001 · Difference in least squares mean: -185.99 · 95% CI -199.93 to -172.05Analysis presented for ANCOVA based on ranks.

Adverse events

Collected over Up to approximately 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Andexanet Alfa75/263 (28.5%)120/262 (45.8%)198/262 (75.6%)
Usual Care70/267 (26.2%)96/265 (36.2%)200/265 (75.5%)
Most frequent serious events
Showing 10 of 109
Most frequent serious events
EventAndexanet AlfaUsual Care
PneumoniaInfections and infestations14/26216/265
Pneumonia aspirationInfections and infestations14/2627/265
Ischaemic strokeNervous system disorders13/2622/265
Haemorrhage intracranialNervous system disorders8/26211/265
Cerebral haemorrhageNervous system disorders7/26211/265
Myocardial infarctionCardiac disorders8/2621/265
HydrocephalusNervous system disorders7/2624/265
Neurological decompensationNervous system disorders2/2627/265
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/2627/265
SepsisInfections and infestations6/2622/265
Most frequent other events
Showing 10 of 12
Most frequent other events
EventAndexanet AlfaUsual Care
Urinary tract infectionInfections and infestations54/26244/265
HypokalaemiaMetabolism and nutrition disorders40/26228/265
ConstipationGastrointestinal disorders39/26225/265
PneumoniaInfections and infestations28/26225/265
DeliriumPsychiatric disorders20/26226/265
HeadacheNervous system disorders24/26219/265
NauseaGastrointestinal disorders23/26217/265
PyrexiaGeneral disorders23/26222/265
Pneumonia aspirationInfections and infestations19/26216/265
HypertensionVascular disorders18/26219/265

Baseline characteristics

Measured in the Intent-to-Treat Population (ITT), Extended Population, which included all randomized participants according to the randomized treatment.

Age, Continuous
Age, Continuous(years)Andexanet AlfaUsual CareTotal
Mean79.4 ± 8.5178.7 ± 8.6179.0 ± 8.56
Sex: Female, Male
Sex: Female, Male(Participants)Andexanet AlfaUsual CareTotal
Female117128245
Male146139285
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Andexanet AlfaUsual CareTotal
Hispanic or Latino151328
Not Hispanic or Latino227237464
Unknown or Not Reported211738
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Andexanet AlfaUsual CareTotal
American Indian or Alaska Native000
Asian347
Native Hawaiian or Other Pacific Islander000
Black or African American549
White239247486
More than one race000
Unknown or Not Reported161228
08

Study locations

142 sites
  • Research Site
    Fort Lauderdale, Florida 33308, United States
  • Research Site
    Augusta, Georgia 30905, United States
  • Research Site
    Royal Oak, Michigan 48073, United States
  • Research Site
    Troy, Michigan 48085, United States
  • Research Site
    Albany, New York 12208, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Tulsa, Oklahoma 74104, United States
  • Research Site
    Allentown, Pennsylvania 18103, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Austin, Texas 78705, United States
  • Research Site
    Austin, Texas 78712, United States
  • Research Site
    Innsbruck, 6020, Austria
  • Research Site
    Klagenfurt am Wörthersee, 9020, Austria
  • Research Site
    Linz, 4020, Austria
  • Research Site
    Salzburg, 5020, Austria
  • Research Site
    Sankt Pölten, 3100, Austria
  • Research Site
    Vienna, 1020, Austria
  • Research Site
    Belgium, 1200, Belgium
  • Research Site
    Genk, 3600, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Kortrijk, 8500, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Ottignies, 1340, Belgium
  • Research Site
    Calgary, Alberta T2N 2T9, Canada
  • Research Site
    Edmonton, Alberta T6G 2B7, Canada
  • Research Site
    New Westminster, British Columbia V3L 0E3, Canada
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    Hamilton, Ontario L8L 2X2, Canada
  • Research Site
    London, Ontario N6A 5A5, Canada
  • Research Site
    Montreal, Quebec H3A 2B4, Canada
  • Research Site
    Montreal, Quebec H3T 1E2, Canada
  • Research Site
    Québec, Quebec G1J 4Z1, Canada
  • Research Site
    Brno, 656 91, Czechia
  • Research Site
    Ostrava, 703 84, Czechia
  • Research Site
    Praha 5, 150 06, Czechia
  • Research Site
    Aalborg, 9100, Denmark
  • Research Site
    Copenhagen Ø, 2100, Denmark
  • Research Site
    Copenhagen, DK-2400, Denmark
  • Research Site
    Odense C, 5000, Denmark
  • Research Site
    Århus N, 8200, Denmark
  • Research Site
    Helsinki, 00029, Finland
  • Research Site
    Turku, FI-20521, Finland
  • Research Site
    Angers, 49933, France
  • Research Site
    Bordeaux Cedex, 33076, France
  • Research Site
    Bourg en Bresse, 01012, France
  • Research Site
    Clermont Ferrand, 63003, France
  • Research Site
    Lyon, 69437, France
  • Research Site
    Montpellier cedex 5, 34295, France
  • Research Site
    Nancy, 54035, France
  • Research Site
    Paris, 75014, France
  • Research Site
    Paris, 75019, France
  • Research Site
    Suresnes Cedex, 92151, France
  • Research Site
    Toulouse, 31300, France
  • Research Site
    Altenburg, 4600, Germany
  • Research Site
    Augsburg, 86156, Germany
  • Research Site
    Bad Neustadt, 97616, Germany
  • Research Site
    Bochum, 44892, Germany
  • Research Site
    Bonn, 53127, Germany
  • Research Site
    Bremen, 28755, Germany
  • Research Site
    Chemnitz, 9116, Germany
  • Research Site
    Dortmund, 44137, Germany
  • Research Site
    Dresden, 1067, Germany
  • Research Site
    Dresden, 1307, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Essen, 45131, Germany
  • Research Site
    Frankfurt am Main, 60528, Germany
  • Research Site
    Frankfurt, 65929, Germany
  • Research Site
    Giessen, 35392, Germany
  • Research Site
    Goettingen, 37075, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Hamburg, 22291, Germany
  • Research Site
    Hannover, 30625, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Konstanz, 78464, Germany
  • Research Site
    Lübeck, 23538, Germany
  • Research Site
    Lünen, 44534, Germany
  • Research Site
    Mannheim, 68135, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Osnabrück, 49076, Germany
  • Research Site
    Sande, 26452, Germany
  • Research Site
    Stuttgart, 70174, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Alexandroupolis, 68100, Greece
  • Research Site
    Athens, 12462, Greece
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1106, Hungary
  • Research Site
    Budapest, 1134, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Pécs, 7623, Hungary
  • Research Site
    Ashdod, 7747629, Israel
  • Research Site
    Beersheba, 84101, Israel
  • Research Site
    Haifa, 3109601, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Jerusalem, 9372212, Israel
  • Research Site
    Petach-Tikva, 4941492, Israel
  • Research Site
    Tel Aviv, 6423906, Israel
  • Research Site
    Bologna, 40133, Italy
  • Research Site
    Genova, 16132, Italy

Showing the first 100 of 142 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in May 2023, 47 months.

Results were first posted in Jul 2024, 1 year 1 month after primary completion.

Of 34 phase 4 interventional studies under Thrombosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 63. This study's 47 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2018
First posted
Sep 7, 2018
StartActual
Jun 6, 2019
Primary completionActual
May 27, 2023
CompletionActual
Aug 9, 2023
Results first posted
Jul 3, 2024
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03661528
Responsible party
Sponsor
First posted
Sep 7, 2018
Start date
Jun 6, 2019
Primary completion
May 27, 2023
Completion
Aug 9, 2023
Results posted
Jul 3, 2024
Last update
Jul 3, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PRT064445

Start the discussion